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ABSTRACT
Background: Since there is a predilection of some clinical and molecular features 
for a given tumor location, we assessed whether this can be confirmed in late-onset 
colorectal cancer (LOCRC).
Results: Right colon cancers showed features associated with sporadic 
Microsatellite Instability: predominance of female cases and BRAF mutations, and 
an important mucinous component. Left colon cancers developed a higher number 
of polyps and multiple primary CRCs, showed the strongest familial component, and 
had better prognosis. Rectal cancers showed a predominantly sporadic phenotype, 
with worse prognosis and a CpG Island Methylator Phenotype (CIMP)-High. No copy 
number alterations (CNAs) greater than or equal to 50% were observed in this 
LOCRC group, and the most recurrent alterations were losses at 5q13 and 14q11, 
and gains at 7q11, 7q21-q22, 19p13-p12, 19q13 and 20p11-q11. KRAS and PIK3CA 
were the only mutated genes showing differences according to the tumor location, 
mainly for right colon cancers. 
Materials and Methods: We analyzed clinical and molecular characteristics of 
LOCRC at different tumor locations in order to determine if there are differential 
phenotypes related with the location in the colon.
Conclusions: Categorizing LOCRC according to tumor location appears to be an 
adequate first step to resolving the heterogeneity of this subset of CRC. 
                                                   Research Paper
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INTRODUCTION
Colorectal cancer (CRC) is the second leading 
cause of cancer-related deaths in western countries 
[1]. In its pathogenesis, both environmental and 
genetic factors play an important role. Hereditary CRC 
syndromes, such as Familial Adenomatous Polyposis 
(FAP) and Lynch syndrome (LS), are a minority of 
cases within CRC, and sporadic CRC is the key form. 
Sporadic CRC mainly arises through the Chromosomal 
Instability (CIN) pathway, but as the age-of-onset 
increases the two-other main carcinogenetic pathways, 
Microsatellite Instability (MSI) and CpG Islands 
Methylator Phenotype (CIMP), plays increasingly 
important roles in its development [2]. Moreover, these 
three main carcinogenetic pathways (CIN, MSI and 
CIMP) vary according to tumor location, and several 
studies demonstrate that right colon, left colon and 
rectal cancers show genetic and molecular differences 
with divergent underlying carcinogenetic mechanisms 
and risk factors [3, 4]. 
Recent studies have also established clinical, 
genetic and biological differences according to the 
age-of-onset of CRC, suggesting that it should be a 
major criterion for subclassifying CRC [5, 6]. Besides, 
we were able to differentiate two entities within CRC, 
as early-onset CRC (EOCRC) and late-onset CRC 
(LOCRC), with variable cut-points in the literature 
(45 or 50 years old for EOCRC; 70 or 80 years old 
for LOCRC), being ours 45 and 70, respectively [6]. 
LOCRC shows an important increase of epigenetic 
alterations, together with a higher susceptibility for 
carcinogenesis and a higher global mortality, due to 
comorbidities and less use of adjuvant treatments in this 
age group [7]. Nevertheless, it is a group that represents 
a high proportion within CRC and, as expected, it shares 
many features with sporadic cases.  
To date, there are few studies on CRC that focused 
specifically on LOCRC and its characteristics, pointing 
out the need to define clinicopathologic features and 
prognostic factor that should help to guide treatment 
decision-making of this subset of CRC. Moreover, 
apart from those distinct factors according to prognosis, 
some publications underline the fact that the late-of-
onset criteria should not be used when discarding these 
patients for surgery, improving prognosis for LOCRC 
patients in most cases [8]. 
Our group and others have previously defined particular 
features linked to tumor location in EOCRC [3, 9, 10]. 
In the present study, we want to apply these same 
criteria to LOCRC, to examine if tumor location also serves 
to categorize this subtype better. If so, this will provide a 
rationale for investigating possible molecular basis for 
carcinogenesis specific for any of the locations, and thus 
help to advance the clinical management of this subset of 
CRC. 
RESULTS
Global group features 
Clinicopathological and familial features 
Clinical and molecular features of global LOCRC 
have been published before [6] and are shown in Table 1. 
According to the tumor location, right colon and rectum 
lead (39 and 38%, respectively). The remarkable features 
are the low rate of poor differentiated tumors (4%), but 
on the other hand, the considerable rate of mucinous 
component (20%). The higher stage at diagnosis was 
B (49%), with an outstanding rate of associated polyps 
through follow-up (64%), mainly adenomatous (61%). 
Familiar component was low, being most cases sporadic 
(80%).
Molecular features
Molecular global group features have been 
published before [6, 30, 28], and summarized in Table 2. 
Only 9% of cases appeared MSI, mainly associated with 
BRAF mutations. From 90 cases studied for CIMP, the 
main group appeared was CIMP-0 (49%), and the CIMP-
High subgroup was related with the sporadic MSI cases 
previously described.  
A total of 86 samples could be adequately processed 
for Array Comparative Genomic Hybridisation (a-CGH) 
[30]. The results appeared previously as well, and the 
most interesting point that should be underlined was that 
there was no CNA greater or equal to 50% in this group, 
being the most recurrent alterations: losses at 5q13 and 
14q11, and gains at 7q11, 7q21-q22, 19p13-p12, 19q13 
and 20p11-q11. 
Finally, both pathogenic mutations and variants of 
uncertain (or unknown) significance identified by Next 
Generation Sequencing (NGS) are listed in Supplementary 
Table 1. Most frequent mutations are those appearing 
in KRAS, APC and p53, and less frequently in PIK3CA 
(58%, 50%, 45% and 19%, respectively) (Figures 1 and 
2; Supplementary Figures 1 and 2); others did not reach 
the 10%.  
Comparative analysis according to tumor 
location
Clinicopathological and familial features
All these comparative features related with the three 
main tumor location are summarized in Table 1, being 
those showing statistical significance described as follows. 
Comparatively, Right colon cancers were more frequent 
in females (65.8%), displaying an important proportion 
of mucinous component (34%). Left colon cancers were 
younger at age-of-onset (74.86 years-old), with better 
prognosis, and higher mean number of associated polyps 
(5.4). Another interesting aspect of this group was the 
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substantial amount of familial cancer component, mainly 
linked with LS-related neoplasms (27%). Finally, rectal 
cancers showed sporadic phenotype according to familial 
cancer history, with worse prognosis:  Free Disease 
Survival (FDS) was minor for rectal locations (Mean: 
16.25 months, compared with left colon cancer, 31.68) (p 
= 0.059), as well as the Overall Survival (OS) (mean: 31.67 
months, compared with left colon cancers, 31.68 months) 
(p = 0.024). Seventy-five percent of deaths were colorectal 
cancer-related deaths, mainly due to rectal cancers (52.38%).
Table 1: Morphological and clinical description of CRC in LOCRC according to tumor location
Late-onset CRC 
n (%)
Right Colon
n (%)
Left Colon
n (%)
Rectum
n (%) p (χ
2)
Patients 97 (100) 38 (39.2) 22 (22.7) 37 (38.1)
Mean Age at Onset 
(Years, SD)
77.92
(5.73)
79.08
(6.01)
74.86
(4.96)
78.54
(5.36) 0.015
Gender
         Male
         Female
50 (51.5)
47 (48.5)
13 (34.2)
25 (65.8)
14 (63.6)
8 (36.4)
23 (62.2)
14 (37.8)
0.023
Grade of 
differentiation:
    Well
    Medium
    Poor
21/90 (23.3)
65/90 (72.2)
4/90 (4.4)
10/35 (28.6)
22/35 (62.9)
3/35 (8.6)
5/22 (22.7)
17/22 (77.3)
0/22 (0)
6/33 (18.2)
26/33 (78.8)
1/33 (3)
NS
Mucosecretion
Signet-Ring Cells
18/91 (19.8)
2/91 (2.2)
12/35 (34.3)
0/35 (0)
2/22 (9.1)
0/22 (0)
4/34 (11.8)
2/34 (5.9)
0.022
NS
Stage (UICC) :
                I
               II
              III
              IV
Global Survival  
(months, SD)
Disease-Free 
Survival (months, 
SD)
5 (5.3)
46 (48.9)
24 (25.5)
19 (20.2)
69,83 (11.23)
 
21.68 (22.33)
2 (5.3)
22 (57.9)
8 (21)
6 (15.8)
 
45,94 (4.50)
20.16 (14.49)
1 (4.5)
8 (36.4)
10 (45.5)
3 (13.6)
96,95 (10.26)
31.68 (34.91)
2 (5.6)
18 (50)
6 (16.7)
10 (27.8)
31,67 (3.87)
16.25 (14.48)
NS
0.024
NS
Associated Polyps
 Mean number 
(SD)
Type:
    Adenomatous
    Hyperplastic
    Mixed
62/97 (63.9)
2.70 (4.67)
38/62 (61.3)
6/62 (9.7)
18/62 (29)
24/38 (63.2)
1.78 (2.17)
13/24 (54.2)
3/24 (12.5)
8/24 (33.3)
13/22 (59.1)
5.40 (7.67)
7/13 (53.8)
0/13 (0)
6/13 (46.2)
25/37 (67.6)
2.0 (3.52)
18/25 (72)
3/25 (12)
4/25 (16)
NS
NS
NS
Multiple Primary 
Neoplasms
Synchronous and/
or Metachronous 
CRCs
33/97 (34)
21/97 (21.6)
15/38 (39.5)
9/38 (23.7)
9/22 (40.9)
 
8/22 (36.4)
9/37 (24.3)
4/37 (10.8)
NS
NS
Family history of 
Cancer
Amsterdam II
LS neoplasms
Non-LS neoplasms
Sporadic
1/97 (1)
12/97 (12.4)
6/97 (6.2)
78/97 (80.4)
1/38 (2.7)
6/38 (15.8)
1/38 (2.7)
28/38 (73.7)
0/22 (0)
6/22 (27.3)
2/22 (9.1)
12/22 (55.5)
0/37 (0)
0/37 (0)
3/37 (8.1)
34/37 (91.9)
0.002
Abbreviations: LOCRC: Late-onset Colorectal Cancer. CRC: Colorectal Cancer. SD: Standard Deviation. LS: Lynch 
Syndrome.
Oncotarget15305www.oncotarget.com
Molecular features
Everything related with molecular features are 
described in Table 2. As we have mentioned before, 
nine cases showed MSI (9.3%), with only one of them 
due to a MMR-germline mutation and being seven of the 
others due to BRAF mutations and/or Hypermethylation 
of MLH1 promoter, most of which were in the Right 
colon (p =  0.023). CIMP-High tumors reached only 24%, 
with an important amount of them mainly located at the 
rectum. According to the molecular classification, the 
most frequent category was MSS-CIMP-Low-0, reaching 
almost 86% of all Left colon cancers. Interestingly, 
another important one was MSS-CIMP-High within rectal 
tumors, with a 36% (p =  0.002). 
According to the CIN, the location with the largest 
was right colon, not only talking about Genomic Instability 
Index (GII), but also in Copy Number Variations (CNV) 
per cases (data not shown). Meanwhile, left colon cancers 
show an interesting low Chromosomal Instability (CI), 
and rectal tumors mannered as an intermediate location, 
excluding the high mean of whole altered chromosomes. 
Differences did not show statistical significance maybe 
due to the intrinsic CIN shown already associated to the 
aging. 
Minimum recurrently lost or gained regions at the 
different locations are shown in Supplementary Table 2. 
Moreover, those most frequent altered chromosomal 
regions for the three cancer locations and the correlative 
cancer genes codified within are listed in Supplementary 
Tables 3, 4 and 5. Recurrent gains and losses were more 
slightly frequent in right-sided LOCRCs, followed by 
rectal cases. The only recurrent regions that were observed 
in all three tumor locations were gains of 7q11.22-11.23, 
and 20q11.1-q11.23. Four regions were common to 
right- and left-sided LOCRCs: losses at 18q12.1-12.2, 
18q21.1 and 18q22.1-23, and gains at 7p22.1. Only two 
were common to left-sided and rectal LOCRCs: losses at 
5p15.33-15.31 and alterations in 1q21.1-21.2. Finally, a 
high proportion of altered regions were common between 
right colon and rectal cancers. Individually, the most 
frequent altered regions for each location were: gains at 
7q11.21 and 7q11.23 and losses at 18q22.1-22.3 in right-
sided LOCRCs; losses at 10q11.21-11.23 in left-sided 
LOCRCs; and gains at 7q11.22-11.23 in rectal LOCRCs.
Talking about pathogenic mutations, only KRAS and 
PIK3CA showed statistical differences (Supplementary 
Table 1): KRAS appeared scarcely in left colon cancer 
(29%), while right colon and rectum showed more than 
70% and 60%, respectively; and PIK3CA showed a 
decreasing progression from right colon to rectum (33%, 
14% and 9%)(Figures 1 and 2). 
DISCUSSION
CRC is a heterogeneous disease with different 
outcomes and drug responses. Subclassification according 
to age of onset and tumor location could have applications 
in terms of diagnosis, prevention and therapy. LOCRC 
appeared as an important proportion of CRC that is why 
should be a subset in which focused on. In the general 
group, without applying location criteria, we found some 
already-known features, as could be the association 
with polyp’s development during the follow-up, and the 
sporadic forms predominance. Looking for the main 
molecular pathways, the low rate of MSI cases, due mainly 
to sporadic forms, in an intimate relation with CIMP-High 
have been already published before [11]. The absence of 
a predominant altered region within the a-CGH analysis, 
all of which do not reach a 50%, talk about the possible 
heterogeneity of this group of age. Some of them have 
been already related with CRC, but in studies without age-
of-onset criteria, as loss of 5q13 is [12], or alterations in 
7q21, associated with no-responder to neoadjuvant therapy 
for rectal cancer [13]. 
As we have mentioned before, we have recently 
published the differential features for EOCRC according 
to the tumor location, appearing some interesting subsets 
within this age-of-onset [3]. In relation with LOCRC, some 
differences have also emerged.  As expected, Right colon 
cancers fulfilled those features associated with sporadic 
MSI-CRC [14]: Predominance of female cases and 
BRAF mutations, with an important amount of mucinous 
component, although, surprisingly, CIMP-High appeared 
more in rectal cases. While Left colon cancers developed 
Figure 1: Lollipop plot for KRAS mutations according to the tumor location.
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a higher number of polyps and Synchronous and/or 
Metachronous (SCRCs and/or MCRCs), with a familial 
cancer component, and better prognosis, maybe related 
with the high number of polyps’ development, and a more 
severe follow-up. Rectal cancers show a predominantly 
sporadic phenotype, with worse prognosis. 
Also, it is important to underline the fact of the 
higher CIN of the Right colon group, in contrast with 
what it is published, a low CIN due to the MSI component 
in this location, talking without any age-criterion [15]. 
This aspect is linked with one interesting point related 
with the most frequent altered chromosomal segments 
within LOCRC population, and for every tumor location. 
Most of them, showed in Supplementary Table 2, are 
related with some of the identified Common Fragile Sites 
(FRA) and suggests that these are hotspots of genomic 
instability leading to inactivation of genes encoded within 
them, or as that FRA are functional units and that loss 
of the encoded genes confers selective pressure, leading 
to cancer development [16]: e.g. the most frequent and 
Table 2: Molecular features of LOCRC according to tumor location
Late-onset CRC
n (%)
Right Colon
n (%)
Left Colon
n (%)
Rectum
n (%)
p (χ2)
MSI
MMR  genes mutations
9/97 (9.3)
1/97 (1)
7/38 (18.4)
1/38 (2.6)
2/22 (9.1)
0/22 (0)
0/37 (0)
0/37 (0)
0.023
NS
BRAF mutation 7/97 (7.2) 5/38 (13.2) 1/22 (4.5) 1/37 (2.7) NS
CIMP1
     CIMP-0
     CIMP-Low
     CIMP-High
44/90 (48.9)
24/90 (26.7)
22/90 (24.4)
17/36 (47.2)
12/36 (33.3)
7/36 (19.4)
14/21 (66.7)
4/21 (19)
3/21 (14.3)
13/33 (39.4)
8/33 (24.2)
12/33 (36.4)
NS
Molecular 
Classification
    MSI- CIMP-High
    MSI- CIMP-Low-0 
    MSS- CIMP-High
    MSS- CIMP-Low-0
7/90 (7.8)
2/90 (2.2)
15/90 (16.7)
66/90 (73.3)
5/36 (13.9)
2/36 (5.6)
2/36 (5.6)
27/36 (75)
2/21 (9.5)
0/21 (0)
1/21 (4.8)
18/21 (85.7)
0/33 (0)
0/33 (0)
12/33 (36.4)
21/33 (63.6)
0.002
GENOMIC 
INSTABILITY2
        GII
        Gains
        Losses
        Normal
 
Mean of whole altered 
chromosomes
0.147055
0.200192
0.652745
3.36
0.183649
0.249820
0.566522
3
0.101056
0.114539
0.784362
1.39
0.133332
0.194276
0.672383
3.76
NS
NS
1 Ninety cases were analysed for the global group.
2 Eighty-six cases were analysed for the global group.
Abbreviations: LOCRC: Late-onset Colorectal Cancer. MSI: Microsatellite Instability. MMR: Mismatch Repair genes. MSS: 
Microsatellite Stability. GII: Genomic Instability Index. SD: Standard Deviation.
Figure 2: Lollipop plot for PIK3CA mutations according to the tumor location.
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shared chromosomal segments by the three colon locations 
comprises FRA 7B and FRA 20Ad [17, 18]. This may be 
in relation with the instability component associated with 
aging exhibited by this subgroup of tumors. Unexpectedly, 
Left-sided colon cancer appeared as those with the lowest 
CIN between the three locations. Some other frequent 
alterations within LOCRC have been already associated 
with CRC. Gains in 7q11.21, frequent in our right-colon 
LOCRC, have been associated with LS cases as a whole 
[19]. Moreover, frequents also in Right colon locations 
were losses at 18q22.1-22.3, a region whose alteration 
may be useful as a predictor of benefit from adjuvant 
fluorouracil therapy [20]. Another, as alteration in 18q21.1, 
common between right and left colon cancers, has been 
already connected with a higher risk of CRC [21]. Finally, 
in one region frequently gained in the three locations, 
20q11.1-11.23, is located SRC, a proto-oncogene whose 
variation determine progression in CRC [22]. 
Most frequent mutations appeared in KRAS, APC and 
p53, and less frequently in PIK3CA, but only the first one 
overcoming the 50%. A recent study published by Shimada 
et al. [23], analyzed differences between CRC -without age-
of-onset criterion-, according to the tumor location, and 
within these, studied pathogenic mutations in main genes. 
They got higher proportions of gene mutations, likening 
with our results. Nevertheless, although they did not distinct 
rectal from left colon cancers in the comparative analysis, 
differences in PIK3CA and KRAS are correlative with ours, 
except the high proportion of KRAS also seen in rectal 
location within our population. Other genes, however, did 
not show differences, compared with the results published 
by Shimada et al. [23], showing APC and p53 higher 
rates in right colon cancers, within others. This apparent 
less importance of pathogenic mutations in most frequent 
genes, compared with CIN, may be due, between others, to 
a more important role of this last carcinogenetic pathway in 
LOCRC, more illustrated by right colon location.   
All these findings suggest the importance and 
in some manner, the need of categorize LOCRC, as 
we confirmed within EOCRC, according to the tumor 
location. Not only because phenotypical differences 
appear from clinical and familial point of views. In the 
same way that the molecular basis of sporadic MSI cases 
stays all together in Right-colon category, some specific 
CNA for each location could be useful as a starting 
point for future approaches in order to find out specific 
molecular alterations within the heterogenous group of 
CRCs, as LOCRC is. 
MATERIALS AND METHODS 
Families, samples and data collection 
A total of 100 consecutive individuals with CRC 
diagnosed at an age of 70 years or older were collected 
from our institution, starting from January 2002, excluding 
3 due to the diagnosis of FAP. They were considered the 
index case of each family. All patients, or a first degree 
relative in case of death of the index case, provided written 
consent. Personal and clinicopathologic information 
was obtained including age of onset, gender, location 
of the CRC (right/left colon or rectum), grade of cell 
differentiation (low, medium or high), mucin production, 
the presence of “signet ring” cells, modified Astler-
Coller stage, the existence of polyps during follow-up, 
type of polyps (adenomatous, hyperplastic and mixed), 
the presence of SCRCs or MCRCs, and the presence of 
primary multiple neoplasms in the index case.  
To analyze the antecedents of cancer, families 
were classified into four groups: a) families fulfilling the 
Amsterdam II criteria for LS [10]; b) families with mainly 
aggregation -one in first-degree or two in second-degree 
family members- of LS-related neoplasms; c) families 
with mainly aggregation of LS-unrelated neoplasms; 
d) cases without oncological antecedents; these were 
considered sporadic cases. 
Follow-up was at least 5 years from surgery, defining 
FD and OS, recurrence and cancer-related death for each case. 
Microsatellite instability and mutational analysis
MSI analysis was performed using the Bethesda 
panel [24, 25]. The five microsatellite markers were 
PCR amplified, and fluorescently labeled fragments 
were evaluated using a 3100-Avant genetic analyzer 
(Applied Biosystems, Foster City, CA, USA); data 
were analyzed using GeneMapper software version 3.5 
(Applied Biosystems). Tumors were considered as MSI 
when showing high-frequency MSI (MSI-H) (two or 
more of the five markers showing instability), while the 
rest were classified as MSS. MSI cases were screened 
for germline mutations in the MMR genes MLH1, MSH2 
and MSH6 by denaturing gradient gel electrophoresis 
using a DCode system (Bio-Rad Laboratories, Hercules, 
CA, USA), by denaturing high performance liquid 
chromatography using a Varian ProStar system (Varian 
Australia Pty Ltd., Melbourne, Australia), or by high-
resolution melting analysis using a LightCycler 480 
real-time PCR system (Roche, Mannheim, Germany). 
Primers and denaturing and melting conditions were as 
previously reported, with slight modifications [26]. When 
an anomalous band or pattern was observed by denaturing 
gradient gel electrophoresis, denaturing high-performance 
liquid chromatography, or high-resolution melting, the 
PCR product of the fragment was sequenced using the 
BigDye Terminator v3.1 cycle sequencing kit (Applied 
Biosystems) and was analyzed using an ABI Prism 3130 
genetic analyzer (Applied Biosystems). MSI sporadic 
cases were identified by determining the methylation 
status of the MLH1 gene promoter and/or determination 
of BRAF mutational status. Methods carried out were 
described in previous publications [6]. 
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Analysis of CpG island methylation phenotype 
panel
Methylation status of promoter regions of the CIMP 
panel genes: CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, 
NEUROG1, RUNX3 and SOCS1 were studied by means of 
methylation-specific multiplex ligation-dependent probe 
amplification36 using the SALSA MLPA kit (ME042-B1; 
MRC-Holland, Amsterdam, The Netherlands) following the 
manufacturer’s recommended procedure. The methylation-
specific multiplex ligation-dependent probe amplification 
products were resolved by capillary electrophoresis using 
a 3100-Avant genetic analyzer, and peaks were analyzed 
using GeneMapper software version 3.5. The methylation 
index at a specific CpG locus was calculated by dividing the 
normalized area of a given HhaI-digested probe sample and 
the undigested equivalent. CIMP-High was defined as the 
presence of  ≥ 6/8 methylated promoters, CIMP-Low as 1/8 
to 5/8 methylated promoters, and CIMP-0 as the absence 
(0/8) of methylated promoters. 
Molecular classification
According to the MSI and CIMP status, we 
classified both groups (early-onset and elderly CRC) into 
four categories, because differences between MSI-L and 
MSS are subtle and differences between CIMP-Low and 
CIMP-0 are also subtle: (MSI/CIMP-High); (MSI/CIMP-
Low/0); (MSS/CIMP-High); (MSS/CIMP-Low/0) [27].
Chromosomal instability: array comparative 
genomic hybridization (aCGH)
CGH was performed using NimbleGen 
oligonucleotide microarrays (Roche NimbleGen, Inc., 
Reykjavik, Iceland) in order to identify CNA, and has 
been described before. The degree of genomic instability 
has been already described, as well, in the same work 
[28], and have been included in the Gene Expression 
Omnibus (http://www.ncbi.nlm.nih.gov/geo/). Correlative 
cancer genes codified within those most frequent altered 
chromosomal regions for the three cancer locations are 
shown in corresponding tables [29].
Next generation sequencing (NGS) 
Ion torrent PGM library preparation 
An Ion Torrent adapter-ligated library was 
generated using the Ion AmpliSeq Library Kit 2.0 and 
the Ion AmpliSeq Cancer Hotspot Panel version 2 
(Thermo Fisher Scientific, Rev. B.0; MAN0006735). 
Briefly, 2 μL of 5X Ion AmpliSeq™ HiFi mix, 2 μL of 
5X Ion AmpliSeq™ Primer Pool and 5 ng of gDNA per 
reaction were mixed together and amplified following 
the temperature conditions provided by the manufacturer. 
Then, primer sequences were partially digested by adding 
1 μL of FuPa Reagent and loaded in a thermal cycler under 
the conditions detailed in the user guide. Finally, each 
library was marked with a unique adapter provided in Ion 
Xpress™ barcode adapters 1-96 Kit (Life Technologies) in 
a reaction mixture containing 2 μL of Switch Solution, 1 μL 
of diluted barcode and 1 μL of DNA Ligase, also under the 
temperature conditions provided by the manufacturer. 
After AMPure bead (Beckman Coulter, Brea, CA, 
USA) purification, the concentration of the library (in a 
100-fold dilution) was determined using the Ion Library 
TaqMan quantitation assay kit (Thermo Fisher Scientific) 
in a 7500 Real-Time PCR System (Thermo Fisher 
Scientific, Foster City, CA, USA). Each sample was run 
in a minimum of two replicates. 
Emulsion PCR
Sample emulsion PCR and enrichment were 
performed using the Ion PGM™ Template OT2 200 Kit 
and Ion One Touch™ 2 System (Life Technologies). We 
followed the manufacturer’s instructions except for the 
concentration of the pooled libraries which in this work 
was set at 9pM. 
Sequencing on the Ion torrent PGM platform 
All barcoded samples were sequenced using the Ion 
PGM™ Hi-Q™ Sequencing Kit (Life Technologies) in an 
Ion Torrent PGM instrument (Life Technologies) with Ion 
318™ v2 chips (Life Technologies). 
Chip loading procedure was performed according 
to the user guide for the Ion PGM™ Hi-Q™ Sequencing 
Kit (Life Technologies). A maximum of 16 samples were 
loaded on a single chip per sequencing run. 
Bioinformatics processing and data analysis
Base calling and alignment to the human genome 
(hg19) were executed with the Torrent Suite Software v.4.0 
using the variant caller plugin. Variants were annotated 
using Ion Reporter and each mutation was verified in the 
Integrative genome viewer (IGV) from the Broad Institute 
(http://www.broadinstitute.org/igv/) [30]. 
Statistical analyses
Continuous variables were expressed as mean values 
plus/minus standard desviation (SD), and categorical 
variables were expressed as number of cases and their 
percentage. Differences were considered significant when 
p < 0.05. For associations between colon location and other 
discrete variables, statistical analyses were performed using 
Pearson’s Chi Square (χ2). Test for parametric variables, 
and Fisher’s Exact Test for non-parametric variables. 
When those features were continuous variables, Student’s 
t test was used. Survival analyses were also carried out by 
Kaplan–Meier test. The SPSS v.11.5 for Windows (SPSS, 
Inc., Chicago, IL, USA) statistical package was used.
For the CGH analysis, statistics were as follows: For 
identifying significant minimum regions, both univariate 
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and multivariate analysis were carried out. Regarding the 
univariate analysis, unconditional logistic regression was 
carried out for each candidate region. For the multivariate 
analysis, each of the regions was tested separately, 
including other relevant clinical variables. Location was 
considered as a factor in all the analysis carried out. This 
analysis was performed in R Statistics Software [31].
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